COVID-19 has revealed the importance of lowering barriers to vaccine development globally. On May 25, 2021, some of the world's leaders in science, economics, and policy will discuss how open-source vaccinology could lower costs, increase participation, catalyze innovation, and improve access to future vaccines.

The Rapid Vaccine Deployment Collaborative (RaDVaC) began in March 2020 to address the critical lack of accessible vaccine research, primarily by producing open-source protocols for vaccine candidates that could be rapidly designed, produced, tested, and deployed with minimal cost and minimal lag. Our vaccine candidate designs have been adapted into more than 10 generations within the first year, and RaDVaC has begun to develop tools for researchers around the globe to formalize preclinical (animal) and clinical (human) trials of these open-source vaccine candidates.

Schedule

(All times in Eastern Daylight Time, UTC-4)

Speakers

George Church, PhD

Professor of Genetics, Health Sciences and Technology at Harvard Medical School and MIT. Member of RaDVaC.

Jutta Paulus, MEP

Member of European Parliament (Green Party). Pharmacist. Global vaccine access advocate.

Andrew Lo, PhD

Professor of Finance at the MIT Sloan School of Management. Vaccine economist.

Alexander Tabarrok, PhD

Professor at Virginia's George Mason University and Bartley J. Madden Chair in Economics at the school's Mercatus Center. Director of research for the Independent Institute.

Milena Leybold

PhD fellow at the University of Innsbruck, interested in phenomena of organizational openness, communication, strategic change, inclusion and exclusion, and Grand Challenges.

Nir Eyal, DPhil

The inaugural Henry Rutgers Professor of Bioethics. Dr. Eyal’s work in global health focuses on health inequalities, health promotion, and research ethics. It engages many bioethics challenges, including healthcare rationing in resource-poor settings, critical health-worker shortages, disaster response, universal health coverage, and ethics in HIV- and emerging-infection trials.

Ben Hurlbut, PhD

Associate professor of biology and society in the School of Life Sciences at Arizona State University. Dr. Hurlbut studies the changing relationships between science, politics and law in the governance of biomedical research and innovation in the 20th and 21st centuries.

Reza Mostofi, PharmD

Director of pharmaceutical engineering at Actoverco.

Dr. Craig Travis, MD

Founder and President of Immugen Pharma.

This event made possible by support from the Bakewell Foundation